Hadeel Saeed Hadi, Shaymaa Abdulzahra Abbas
Hadeel Saeed Hadi1*, Shaymaa Abdulzahra Abbas2
1Apharmacist, Wasit Health Department, Ministry of Health and Environment, Wasit, Iraq.
2Department of Clinical Laboratory Sciences, Collage of Pharmacy, University of Baghdad, Baghdad, Iraq.
Volume - 16,
Issue - 5,
Year - 2023
Background: Breast cancer is a malignant tumor arising from epithelial cells of glandular lacteferons ducts or terminal ductilobular unit (TDLM) of the breast which is affected by the oxidative stress and the defensive mechanisms against it. Objective: to reveal the correlation between the levels of superoxide dismutase (CuZn SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GR), reduced glutathione (GSH) and sulfhydryl groups (SH) with breast cancer with/without metast. Methods: A case control study was performed on 30 female patients with metastasized breast cancer, 30 female patients with non- metastasized breast cancer and 30 female patients with benign breast tumor. All patients were recruited from Al-Karama teaching hospital at Wasit city in Iraq, for the period from October 2021 to February 2022. Results: The levels of GSH-PX, GR, GSH, and sulfhydral groups were significantly reduced in breast cancer patients in comparison with healthy controls whereas SOD levels were upregulated in breast cancer patients in comparison with healthy controls subjected to the current study. Conclusions: It is concluded that the activities of superoxide dismutase (CuZn SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GR), as well as concentrations of reduced glutathione (GSH) and sulfhydryl groups (SH) have a significant impact on the pathogenisis and progression of breast cancer.
Cite this article:
Hadeel Saeed Hadi, Shaymaa Abdulzahra Abbas. Oxiditive Stress biomarkers levels in blood sample of Iraqi Breast cancer patients. Research Journal of Pharmacy and Technology 2023; 16(5):2364-8. doi: 10.52711/0974-360X.2023.00389
Hadeel Saeed Hadi, Shaymaa Abdulzahra Abbas. Oxiditive Stress biomarkers levels in blood sample of Iraqi Breast cancer patients. Research Journal of Pharmacy and Technology 2023; 16(5):2364-8. doi: 10.52711/0974-360X.2023.00389 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-5-48
1. Arjun Patidar, S.C.Shivhare, Umesh Ateneriya, Sonu Choudhary. A Comprehensive Review on Breast Cancer. Asian J. Nur. Edu. & Research. 2012; 2(1):28-32.
2. Saad AH,Rabeea IS, Salih HN. Adherence and Beliefs to Adjuvant Hormonal Therapy in Patients with Breast Cancer: A Cross-Sectional Study(Conference Paper). Iraqi J Pharm Sci. 2021;30(Suppl.):31-39.doi: 10.31351/vol30issSuppl.pp31-39
3. Dange VN, Shid SJ, Magdum CS, Mohite SK. A Review on Breast cancer: An Overview. Asian J. Pharm. Res. 2017; 7(1): 49-51. doi: 10.5958/2231-5691.2017.00008.9
4. Yadav AR, Mohite SK. Cancer- A Silent Killer: An Overview. Asian J. Pharm. Res. 2020; 10(3):213-216. doi: 10.5958/2231-5691.2020.00036.2
5. Jayashree V, Velraj M. Breast Cancer and various Prognostic Biomarkers for the diagnosis of the disease: A Review. Research J. Pharm. and Tech. 2017; 10(9): 3211-3216. doi: 10.5958/0974-360X.2017.00570.4
6. Sudhakar GK, Pai V, Pai A. An overview on current Strategies in Breast Cancer Therapy. Research J. Pharmacology and Pharmacodynamics. 2013; 5(6): 353-355.
7. Tiwari A, Singh M, Sahu B. Risk Factors for Breast Cancer. International Journal of Nursing Education and Research. 2022; 10(3):276-2. doi: 10.52711/2454-2660.2022.00065.
8. Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care. 2013;8:149–154.
9. Alrubaye YSJ, Mohammed MB, Abdulamir HA. Exosome and Breast Cancer. Research Journal of Pharmacy and Technology. 2022; 15(3):1393-7. doi: 10.52711/0974-360X.2022.00232.
10. Hariramani N, Jayanthi S. A Systematic Review of Intrinsic Factors and its Influence in Breast Cancer. Research J. Pharm. and Tech. 2018; 11(8): 3543-3546. doi: 10.5958/0974-360X.2018.00654.6.
11. Stewart BW, and Wild CP. World Cancer Report 2014. Geneva, Switzerland: WHO Press; 2014.
12. Assaf A, Al-Saleh J. Evaluation the Serum vascular endothelial growth factor C (VEGF-C) value in breast cancer patients. Research J. Pharm. and Tech. 2020; 13(9):4277-4279. doi: 10.5958/0974-360X.2020.00755.6
13. Karale PA, Karale MA, Utikar MC. Advanced Molecular Targeted Therapy in Breast Cancer. Res. J. Pharmacology and Pharmacodynamics. 2018; 10(1): 29-37. doi: 10.5958/2321-5836.2018.00006.X.
14. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31-42. doi: 10.3322/caac.21320.
15. Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. Role of Glutathione in Cancer: From Mechanisms to Therapies. Biomolecules. 2020;10(10):1429. doi: 10.3390/biom10101429.
16. Khan MA, Tania M, Zhang D, Chen, H. Antioxidant enzymes and cancer. Chinese Journal of Cancer Research. 2010;22(2): 87–92. doi:10.1007/s11670-010-0087-7.
17. Zhang ML, Wu HT, Chen WJ, Xu Y, Ye QQ, Shen JX, Liu J. Involvement of glutathione peroxidases in the occurrence and development of breast cancers. J Transl Med. 2020;18(1):247. doi: 10.1186/s12967-020-02420-x..
18. Eryilmaz MA, Kozanhan B, Solak I, Çetinkaya and D, Neselioglu S, Erel &. Thiol-disulfide homeostasis in breast cancer patients. J Can Res Ther. 2019;15:1062-6.
19. Sahu A, Varma M, Kachhawa K. A Prognostic Study of MDA, SOD and Catalase in Breast Cancer Patients. International J. Sci. Res. 2015;4 (5):157-159.
20. Lunetti P, Di Giacomo M, Vergara D, De Domenico S, Maffia M, Zara V, Capobianco L, Ferramosca A. Metabolic reprogramming in breast cancer results in distinct mitochondrial bioenergetics between luminal and basal subtypes. FEBS J. 2019;286(4):688-709. doi: 10.1111/febs.14756.